Regen Biopharma Financials
This page shows Regen Biopharma (RGBPP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Flat revenue and shrinking research spend show burn management, while liquidity still depends on external financing.
Earlier in the recent period, reported earnings and core cash economics diverged: net income reached$1.2M even though operating cash flow was-$174K . With revenue later still essentially unchanged, that earnings cushion had vanished; operating cash burn improved from-$752K to-$384K , but the business still did not fund itself.
Loss reduction came from spending restraint, not scale. Revenue stayed near
The current ratio of 0.04x means short-term obligations vastly exceed near-term resources. Cash was only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Regen Biopharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Regen Biopharma has an operating margin of -143.1%, meaning the company retains $-143 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -176.4% the prior year.
Regen Biopharma's revenue grew a modest 0.0% year-over-year to $237K. This slow but positive growth earns a score of 33/100.
Regen Biopharma carries a low D/E ratio of -1.04, meaning only $-1.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Regen Biopharma's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Regen Biopharma passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Regen Biopharma generates $0.30 in operating cash flow (-$384K OCF vs -$1.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Regen Biopharma earns $-2.1 in operating income for every $1 of interest expense (-$339K vs $158K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Regen Biopharma generated $237K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Regen Biopharma reported -$1.3M in net income in fiscal year 2025. This represents a decrease of 90.7% from the prior year.
Regen Biopharma earned $-0.05 per diluted share (EPS) in fiscal year 2025. This represents an increase of 68.8% from the prior year.
Cash & Balance Sheet
Regen Biopharma held $70K in cash against $0 in long-term debt as of fiscal year 2025.
Regen Biopharma had 39M shares outstanding in fiscal year 2025. This represents an increase of 648.8% from the prior year.
Margins & Returns
Regen Biopharma's operating margin was -143.1% in fiscal year 2025, reflecting core business profitability. This is up 33.3 percentage points from the prior year.
Regen Biopharma's net profit margin was -538.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 256.3 percentage points from the prior year.
Capital Allocation
Regen Biopharma invested $12K in research and development in fiscal year 2025. This represents a decrease of 92.4% from the prior year.
RGBPP Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59K0.0% | $59K-0.5% | $59K+0.5% | $59K0.0% | $59K0.0% | $59K-0.5% | $59K+0.5% | $59K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2K-98.9% | $210K | N/A | N/A | $0 | $0-100.0% | $34K+3.2% | $33K |
| SG&A Expenses | $32K-86.2% | $232K+1206.5% | $18K-42.2% | $31K+130.0% | $13K+0.2% | $13K+134.8% | -$38K-332.2% | $16K |
| Operating Income | -$154K+72.1% | -$552K-348.3% | -$123K-201.9% | -$41K+64.0% | -$113K-84.7% | -$61K+28.1% | -$85K+20.9% | -$108K |
| Interest Expense | $27K+3.1% | $27K-69.1% | $86K+248.9% | $25K+10.3% | $22K-11.9% | $25K+26.4% | $20K+14.3% | $18K |
| Income Tax | $0 | $0 | N/A | N/A | $0 | $0 | N/A | N/A |
| Net Income | $992K+202.5% | -$968K-69.1% | -$572K-242.2% | -$167K-764.4% | -$19K+96.2% | -$515K-94.6% | -$265K-103.6% | -$130K |
| EPS (Diluted) | $0.00 | $-0.01 | N/A | $-0.01 | $0.00+100.0% | $-0.13 | N/A | $-0.03 |
RGBPP Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $260K+9.8% | $237K-13.7% | $275K+39.5% | $197K+16.1% | $169K-11.5% | $191K+18.8% | $161K-5.3% | $170K |
| Current Assets | $260K+9.8% | $237K-13.7% | $275K+53.3% | $179K+18.0% | $152K-12.6% | $174K+21.2% | $143K-5.9% | $152K |
| Cash & Equivalents | $271-94.1% | $5K-93.4% | $70K+3849.7% | $2K0.0% | $2K+1204.4% | $135-81.1% | $716-98.8% | $62K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $260K+11.8% | $232K+13.4% | $205K+15.7% | $177K+18.3% | $150K+22.4% | $122K+28.9% | $95K+41.3% | $67K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.6M-17.5% | $6.8M+3.9% | $6.6M+9.0% | $6.0M+2.5% | $5.9M0.0% | $5.9M+9.1% | $5.4M+0.9% | $5.3M |
| Current Liabilities | $5.6M-17.5% | $6.8M+3.9% | $6.6M+9.0% | $6.0M+2.5% | $5.9M0.0% | $5.9M+9.1% | $5.4M+0.9% | $5.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.4M+18.5% | -$6.6M-4.6% | -$6.3M-8.0% | -$5.8M-2.1% | -$5.7M-0.3% | -$5.7M-8.8% | -$5.2M-1.2% | -$5.2M |
| Retained Earnings | -$21.7M+4.4% | -$22.7M-4.5% | -$21.7M-2.7% | -$21.1M-0.8% | -$21.0M-0.1% | -$20.9M-2.5% | -$20.4M-0.3% | -$20.4M |
RGBPP Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$63K+68.1% | -$198K-23.7% | -$160K-185.8% | -$56K+44.7% | -$101K-52.5% | -$66K+68.0% | -$207K-20.1% | -$173K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $59K-55.7% | $133K-41.6% | $228K+307.0% | $56K-45.6% | $103K+56.3% | $66K-55.0% | $146K-6.5% | $156K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RGBPP Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -260.2%+673.7pp | -933.9%-726.6pp | -207.3%-138.3pp | -69.0%+122.9pp | -191.9%-88.0pp | -103.9%+39.9pp | -143.9%+38.9pp | -182.8% |
| Net Margin | 1679.4%+3318.0pp | -1638.6%-674.3pp | -964.3%-681.1pp | -283.2%-250.5pp | -32.8%+839.8pp | -872.6%-426.4pp | -446.2%-225.9pp | -220.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 381.2%+789.5pp | -408.2%-199.8pp | -208.4%-123.5pp | -85.0%-73.6pp | -11.4%+257.8pp | -269.3%-104.8pp | -164.5%-88.0pp | -76.5% |
| Current Ratio | 0.05+0.0 | 0.030.0 | 0.04+0.0 | 0.030.0 | 0.030.0 | 0.030.0 | 0.030.0 | 0.03 |
| Debt-to-Equity | -1.05-0.0 | -1.040.0 | -1.040.0 | -1.030.0 | -1.030.0 | -1.030.0 | -1.030.0 | -1.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Regen Biopharma's annual revenue?
Regen Biopharma (RGBPP) reported $237K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regen Biopharma's revenue growing?
Regen Biopharma (RGBPP) revenue grew by 0% year-over-year, from $237K to $237K in fiscal year 2025.
Is Regen Biopharma profitable?
No, Regen Biopharma (RGBPP) reported a net income of -$1.3M in fiscal year 2025, with a net profit margin of -538.8%.
What is Regen Biopharma's operating margin?
Regen Biopharma (RGBPP) had an operating margin of -143.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Regen Biopharma's net profit margin?
Regen Biopharma (RGBPP) had a net profit margin of -538.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Regen Biopharma's operating cash flow?
Regen Biopharma (RGBPP) generated -$384K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Regen Biopharma's total assets?
Regen Biopharma (RGBPP) had $275K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Regen Biopharma spend on research and development?
Regen Biopharma (RGBPP) invested $12K in research and development during fiscal year 2025.
What is Regen Biopharma's current ratio?
Regen Biopharma (RGBPP) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Regen Biopharma's debt-to-equity ratio?
Regen Biopharma (RGBPP) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regen Biopharma's return on assets (ROA)?
Regen Biopharma (RGBPP) had a return on assets of -464.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regen Biopharma's cash runway?
Based on fiscal year 2025 data, Regen Biopharma (RGBPP) had $70K in cash against an annual operating cash burn of $384K. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Regen Biopharma's debt-to-equity ratio negative or unusual?
Regen Biopharma (RGBPP) has negative shareholder equity of -$6.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regen Biopharma's Piotroski F-Score?
Regen Biopharma (RGBPP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regen Biopharma's earnings high quality?
Regen Biopharma (RGBPP) has an earnings quality ratio of 0.30x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regen Biopharma cover its interest payments?
Regen Biopharma (RGBPP) has an interest coverage ratio of -2.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Regen Biopharma?
Regen Biopharma (RGBPP) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.